{"gene":"CHRNA7","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":2011,"finding":"CHRFAM7A (the partial duplication of CHRNA7) acts as a dominant negative regulator of α7*nAChR function. Co-expression of α7 and CHRFAM7A in cell lines and Xenopus oocytes caused significant reduction of ACh-evoked current amplitude without reducing α-bungarotoxin binding, indicating formation of non-functional (ACh-silent) receptors. The allosteric modulator PNU-120596 produced a larger increase in ACh-evoked current in cells co-expressing the duplicate, consistent with a population of closed, non-conducting α7 receptors.","method":"Functional electrophysiology (ACh-evoked currents) in cell lines and Xenopus oocytes; radioligand binding with [125I]-α-bungarotoxin; allosteric modulator pharmacology","journal":"Biochemical pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution in heterologous expression systems (cell lines + Xenopus oocytes), multiple orthogonal functional and binding assays in one rigorous study","pmids":["21718690"],"is_preprint":false},{"year":2017,"finding":"In iPSC-derived neural progenitor cells from individuals with 15q13.3 duplications, increased CHRNA7 mRNA expression is associated with higher expression of nAChR-specific and resident ER chaperones, indicating increased ER stress and inefficient receptor assembly, resulting in accumulation of α7 subunits in the ER rather than incorporation into functional cell-surface receptors. Both deletions (haploinsufficiency) and duplications (ER stress/trafficking failure) lead to decreased α7 nAChR-associated calcium flux.","method":"iPSC-derived neural progenitor cells from human subjects with deletions and duplications; calcium flux assay; mRNA expression analysis of chaperones; ER stress markers","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — human iPSC/NPC model with multiple orthogonal methods (Ca2+ flux, transcriptomics, chaperone analysis), single lab but mechanistically rigorous","pmids":["29129316"],"is_preprint":false},{"year":2011,"finding":"CHRNA7 transcription is repressed by the transcription factor AP-2α. A 230-bp proximal promoter fragment necessary for transcription in neuroblastoma cells contains a functional AP-2α binding site; mutation of this site, AP-2α knockdown, and AP-2α overexpression all modulate CHRNA7 transcription. AP-2α binding was confirmed by EMSA, supershift assay, and chromatin immunoprecipitation.","method":"Promoter mutagenesis; AP-2α knockdown and overexpression; EMSA; supershift assay; chromatin immunoprecipitation (ChIP); reporter assay in neuroblastoma cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (mutagenesis, ChIP, EMSA, supershift, KD/OE) in one rigorous study","pmids":["21979958"],"is_preprint":false},{"year":2011,"finding":"DNA methylation of the CHRNA7 proximal promoter inversely correlates with CHRNA7 mRNA expression across human tissue types and cell lines. Treatment with DNA methyltransferase inhibitors (5-aza-2-deoxycytidine, zebularine) restored or increased CHRNA7 expression in cells with hypermethylated promoters, while removal of the methyl donor methionine increased transcription. Bisulfite sequencing confirmed hypermethylation of the proximal promoter in silenced cells.","method":"Bisulfite sequencing PCR; methylation-sensitive restriction enzyme analysis (MSRE); DNMT inhibitor treatment; methyl donor manipulation; qRT-PCR across multiple human tissue types","journal":"Journal of molecular neuroscience : MN","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal epigenetic methods (bisulfite sequencing, MSRE, pharmacological inhibition, methyl donor manipulation) across multiple tissue types in a single rigorous study","pmids":["22052086"],"is_preprint":false},{"year":2005,"finding":"Chrna7 knock-out mice display significantly impaired sperm motility characterized by reduced swimming velocities, failure to maintain vigorous swimming, and lower levels of hyperactivated swimming, with no differences in sperm number, morphology, viability, or spontaneous acrosome reaction rate. Fluorescent α-bungarotoxin localized nAChR binding sites (primarily CHRNA7) to the midpiece of sperm, suggesting an ionotropic role in motility.","method":"Chrna7 null mouse genetic model; computer-assisted sperm analysis (CASA); fluorescent α-bungarotoxin-TRITC binding localization; immunoblot; RT-PCR","journal":"Biology of reproduction","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KO mouse with defined motility phenotype and receptor localization data, single lab with multiple methods","pmids":["15944242"],"is_preprint":false},{"year":2012,"finding":"Reduced Chrna7 expression in heterozygous C3H mice leads to significant decreases in hippocampal GAD-65 and GABAA receptor levels, indicating that α7*nAChR expression level controls inhibitory circuit components in the hippocampus.","method":"Chrna7 heterozygous null mice; quantitative Western immunoblotting for GAD-65, GABAA receptors, GABA, GAT-1 in hippocampus","journal":"Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean genetic KO/Het model with defined molecular phenotype, single lab, quantitative protein analysis","pmids":["22314319"],"is_preprint":false},{"year":2014,"finding":"Reduced Chrna7 expression in C3H mice is associated with increases in hippocampal parvalbumin and GAD67, and complex alterations in GABAA receptor subunits (decreased α3, α4, and δ subunits in KO; increased δ in Het; increased γ2 in KO). These changes are sex- and gene-dose-dependent.","method":"Chrna7 wild-type, heterozygous, and knockout C3H mice; quantitative Western immunoblotting for parvalbumin, GAD67, and GABAA receptor subunits","journal":"Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — graded genetic model (WT/Het/KO) with protein-level quantification, single lab","pmids":["24836856"],"is_preprint":false},{"year":2014,"finding":"Gestational choline supplementation improves sensory inhibition via α7 nAChRs; DBA/2 mice heterozygous or null-mutant for Chrna7 fail to show improvement in sensory inhibition with choline supplementation, whereas wild-type mice do. This demonstrates that choline's effect on sensory inhibition requires functional CHRNA7.","method":"Chrna7 null mutation DBA/2 mice; gestational choline supplementation; auditory sensory inhibition testing; [125I]-α-bungarotoxin binding in hippocampus","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis using null mutation model, multiple genotypes, functional behavioral and receptor binding readouts; single lab","pmids":["24462939"],"is_preprint":false},{"year":2017,"finding":"CHRNA7 mediates nicotine-induced signaling in ESCC cancer cells by activating the JAK2/STAT3 signaling pathway to enhance cancer stem cell properties. Dextromethorphan non-competitively inhibited nicotine binding to CHRNA7, while metformin downregulated CHRNA7 expression by antagonizing nicotine-induced promoter DNA hypomethylation.","method":"ESCC cell lines and mouse xenograft models; pharmacological inhibition with dextromethorphan and metformin; Western blot for JAK2/STAT3 pathway; promoter methylation analysis; cancer stem cell assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo models with mechanistic pathway analysis and epigenetic characterization; single lab","pmids":["33603170"],"is_preprint":false},{"year":2017,"finding":"Arctic Aβ40 blocks the neuroprotective effect of nicotine mediated through CHRNA7 by inhibiting the ERK1/2 pathway downstream of CHRNA7. CHRNA7 knockdown by siRNA in SH-SY5Y cells abolished nicotine's neuroprotective effect, and ERK1/2 activation was shown to mediate neuroprotection against oxidative stress via CHRNA7.","method":"Human neuroblastoma SH-SY5Y cells; siRNA knockdown of CHRNA7; pharmacological nicotine stimulation; Western blot for ERK1/2 phosphorylation; cell viability/survival assays; oxidative stress challenge","journal":"Neurochemistry international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with defined pathway readout (ERK1/2), functional neuroprotection assay; single lab, single paper","pmids":["28890319"],"is_preprint":false},{"year":2017,"finding":"VNS-induced neuroprotection in permanent cerebral ischemia requires α7nAChR, which activates the JAK2/STAT3 anti-inflammatory pathway. Pharmacological antagonism of α7nAChR attenuated VNS neuroprotection and decreased p-JAK2 and p-STAT3 levels in ischemic penumbra; α7nAChR agonism partially substituted for VNS.","method":"Rat PMCAO model; α7nAChR antagonist and agonist pharmacology; Western blot for α7nAChR, p-JAK2, p-STAT3; neurological function scoring; cerebral infarct volume measurement","journal":"Medical science monitor","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological gain- and loss-of-function with defined downstream pathway readout in vivo; single lab","pmids":["29274273"],"is_preprint":false},{"year":2013,"finding":"Chrna7 regulates nicotine conditioned place preference in mice. α7 knockout mice show nicotine CPP at sub-threshold doses, while gain-of-function α7 mice do not display nicotine preference. An α7-selective agonist (PHA-543613) dose-dependently blocked nicotine CPP, reversed by the selective antagonist MLA. Chrna7 KO in nucleus accumbens is associated with increased insulin signaling.","method":"Chrna7 KO and gain-of-function mouse models; nicotine conditioned place preference (CPP) behavioral assay; selective α7 agonist/antagonist pharmacology; microarray and qPCR of nucleus accumbens; Western blotting for insulin signaling","journal":"Genes, brain, and behavior","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological approaches with behavioral and molecular readouts; single lab","pmids":["24289814"],"is_preprint":false},{"year":2015,"finding":"CHRNA7 overexpression in LoVo colorectal cancer cells reduces cell migration and invasion via activation of the PI3K/Akt signaling pathway, accompanied by reduced MMP-1 and MMP-9 expression. Blocking PI3K/Akt with LY294002 restored migration/invasion in CHRNA7-overexpressing cells.","method":"CHRNA7 overexpression plasmid in LoVo cells; Transwell migration/invasion assays; Western blot and gelatin zymography for MMP-1, MMP-9; PI3K/Akt pathway pharmacological inhibition (LY294002)","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — overexpression with pharmacological pathway rescue, multiple functional assays; single lab","pmids":["26719016"],"is_preprint":false},{"year":2016,"finding":"Silencing of α7-nAChR (CHRNA7) in AGS gastric cancer cells by siRNA enhances ixabepilone-induced apoptosis, associated with failure to upregulate Bcl-2 and anti-apoptotic Mcl-1 isoform (which are upregulated in scrambled control cells after ixabepilone), and increased cleaved PARP. pAKT and AKT levels were similarly reduced in both groups by ixabepilone.","method":"siRNA knockdown of CHRNA7 in AGS cells; ixabepilone cytotoxicity (MTT assay); flow cytometry/annexin V apoptosis assay; Western blot for AKT, pAKT, Mcl-1, Bcl-2, Bad, Bax, cleaved PARP","journal":"Tumour biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single knockdown approach with Western blot, single lab, limited mechanistic depth","pmids":["26790437"],"is_preprint":false},{"year":2009,"finding":"Chrna7 genotype is linked to α7 nicotinic receptor protein levels (measured by α-bungarotoxin binding) in hippocampus and striatum of F2 mice, but not to α7 RNA levels, suggesting the genetic influence on receptor expression operates at the post-transcriptional level.","method":"F2 mice from C3H/Ibg × DBA/2 cross; quantitative autoradiography of [125I]-α-bungarotoxin binding; quantitative in situ hybridization for α7 RNA; linkage analysis","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic linkage with parallel protein and RNA quantitation in F2 mapping population, multiple brain regions; single lab","pmids":["19368846"],"is_preprint":false},{"year":2011,"finding":"MeCP2-bound chromatin in the 15q11.2-13.3 region physically interacts (via 4C chromatin conformation capture) with two sites flanking CHRNA7 in neurons, and this interaction is lost upon neuronal differentiation. Reduced CHRNA7 expression was found in postmortem frontal cortex from Rett syndrome and autism patients, suggesting that long-range chromatin interactions with the PWS-IC modulate CHRNA7 transcription.","method":"Chromosome conformation capture on chip (4C) in human SH-SY5Y neuroblastoma cells; FISH to confirm PWS-IC/CHRNA7 interaction in neurons; qRT-PCR of CHRNA7 in postmortem human brain (Rett, autism, controls)","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — 4C chromatin interaction confirmed by FISH with functional gene expression correlate in human tissue; single lab","pmids":["21840925"],"is_preprint":false},{"year":2019,"finding":"DNA methylation at multiple regions of the CHRNA7 promoter regulates its transcription. Valproate (a mood stabilizer/HDAC inhibitor) causes demethylation of the CHRNA7 promoter and increases CHRNA7 expression in HeLa cells; combined valproate and nicotine treatment also increases expression in SH-SY5Y cells. Genotypic variants influence methylation levels at the CHRNA7 promoter.","method":"Bisulfite pyrosequencing of CHRNA7 promoter regions in human temporal cortex and cell lines; valproate treatment; qRT-PCR of CHRNA7 expression; correlation of methylation and expression","journal":"Neuroscience letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological demethylation with parallel expression measurement, multiple regions and cell types; single lab","pmids":["30974230"],"is_preprint":false},{"year":2020,"finding":"Farnesyl transferase inhibitor lonafarnib increases α7nAChR expression through inhibiting DNA methylation of CHRNA7 via the Ras-c-Jun-JNK pathway (reduced DNMT1), and independently increases α7nAChR membrane trafficking via CaMKII pathway, leading to enhanced ACh-evoked currents and spatial memory in mice.","method":"In vivo mouse lonafarnib administration; patch-clamp electrophysiology (ACh-evoked I_ACh) in hippocampal CA1; Western blot for DNMT1, p-JNK, p-c-Jun, α7nAChR expression and membrane fractionation; JNK activator and CaMKII inhibitor pharmacology; spatial memory testing","journal":"Frontiers in pharmacology","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — electrophysiology combined with mechanistic pathway analysis (JNK, DNMT1, CaMKII) and pharmacological rescue; single lab","pmids":["33447242"],"is_preprint":false},{"year":2005,"finding":"Chrna7 contains a putative neuronal transcriptional enhancer within the PWS/AS deletion region (intron 4 region). In a transgenic mouse model (TgPWS/TgAS) with deletion of this region, Chrna7 expression in brain is reduced ~1.7-fold, while expression in neonatal liver and spleen is paradoxically increased >15-fold due to transgene immunoglobulin enhancer effects. A Chrna7-Tg fusion transcript mapped the telomeric deletion breakpoint to Chrna7 intron 4.","method":"TgPWS/TgAS transgenic mouse model with large chromosomal deletion; RT-PCR and fusion transcript cloning; quantitative gene expression analysis across brain and peripheral tissues","journal":"BMC genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic model with mapped deletion breakpoint and quantitative expression analysis; single lab","pmids":["16280085"],"is_preprint":false},{"year":2021,"finding":"In iPSC-derived cortical neurons from an autistic proband (but not his unaffected mother) carrying a 15q13.3 CHRNA7 duplication, CHRNA7 duplication causes enhanced neural progenitor proliferation, impaired neuronal differentiation/maturation/migration, and increased ER stress. Neuronal migration deficit could be pharmacologically rescued. Both affected and unaffected carriers showed increased action potential firing and elevated cholinergic activity consistent with increased homomeric CHRNA7 channel activity.","method":"iPSC-derived cortical excitatory and inhibitory neurons from proband, unaffected mother, and unrelated controls; electrophysiology; neuronal migration assay; ER stress markers; pharmacological rescue; single-cell RNA sequencing; gene expression analysis","journal":"BMC biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (electrophysiology, scRNAseq, migration, ER stress, pharmacological rescue) in human iPSC model; single lab but comprehensive","pmids":["34320968"],"is_preprint":false},{"year":2025,"finding":"CHRNA7 and CHRFAM7A are expressed in SOX2+ radial glia progenitors in developing human cortex. nAChR activation increases radial glia (RG) proliferation while decreasing neuronal differentiation; nAChR knockdown has the opposite effect. YAP1 is identified as a downstream effector of nAChR signaling, and YAP1 inhibition reverses nicotine-induced phenotypic alterations in outer radial glia (oRG) cells. CHRNA7 and CHRFAM7A selectively modulate different transcriptional changes in excitatory neurons following nicotine exposure.","method":"Human cortical organotypic slice cultures and dissociated cultures; nAChR pharmacological activation and knockdown; single-cell RNA sequencing; YAP1 inhibitor pharmacological rescue; RG proliferation and differentiation assays","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — human cortical model with pharmacological and genetic manipulation plus scRNAseq; preprint, not yet peer-reviewed","pmids":["bio_10.1101_2025.04.10.647795"],"is_preprint":true},{"year":2018,"finding":"SLURP1 (Secreted Ly-6/uPAR-Related Protein 1) is an endogenous ligand that acts on CHRNA7 in PDAC cells in a CHRNA7-dependent manner with anti-malignant effects, opposing the pro-malignant effects of nicotine. In CHRNA7-high cells, SLURP1 and nicotine abolish each other's effects through functional antagonism without reciprocally interfering with receptor binding or downstream signaling.","method":"CHRNA7-high COLO357 and PANC-1 cancer cell cultures; SLURP1 and nicotine treatment; receptor binding analysis; downstream signaling; cell viability/malignancy assays","journal":"Oncotarget","confidence":"Low","confidence_rationale":"Tier 3 / Weak — cell culture-based functional antagonism without defined binding affinity or structural data; single lab","pmids":["29545933"],"is_preprint":false},{"year":2023,"finding":"GTS-21 (a selective α7 nAChR agonist) promotes regulatory T cell (Treg) development from TCR-activated human CD4+ T cells. CHRNA7 mRNA was profoundly suppressed upon TCR activation (days 4-7 vs day 1), while CHRFAM7A (dominant-negative regulator) remained constant. GTS-21 did not alter CD4+ T cell proliferation but significantly promoted Treg development even with high dupα7 expression.","method":"Human CD4+ T cell culture; TCR activation; GTS-21 pharmacological treatment; flow cytometry for Treg markers; RT-PCR for CHRNA7 and CHRFAM7A mRNA","journal":"International journal of molecular sciences","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pharmacological agonism in human T cells with functional Treg readout; no CHRNA7 KD control; single lab","pmids":["37569633"],"is_preprint":false},{"year":2024,"finding":"α7nAChR activation in human granulosa cells (GCs) reduces hypoxia-induced elevations of IL-6, CXCL8, and IL-1B. CHRNA7 activation with selective agonist PNU 282987 acutely elevated intracellular Ca2+ in GCs, confirming functional receptor expression. Proteomic analysis revealed that CHRNA7 activation decreased several collagen protein levels in hypoxic GCs.","method":"Human granulosa cells from IVF patients; PNU 282987 pharmacological activation; Ca2+ imaging; cytokine mRNA measurement; proteomics; immunohistochemistry in human and primate ovaries","journal":"Biology of reproduction","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional Ca2+ assay confirming receptor activity, pharmacological activation with cytokine and proteomic readouts; single lab","pmids":["40847805"],"is_preprint":false}],"current_model":"CHRNA7 encodes the α7 subunit of the neuronal nicotinic acetylcholine receptor, a homo-pentameric ligand-gated ion channel that, upon activation by ACh, choline, or nicotine, mediates Ca2+ influx and activates downstream pathways including ERK1/2, JAK2/STAT3, PI3K/Akt, and YAP1 signaling; its transcription is regulated by AP-2α-mediated repression and DNA methylation of the proximal promoter; the human-specific partial duplicate CHRFAM7A co-assembles with α7 subunits to form non-conducting receptors that dominantly suppress channel function; receptor surface expression is subject to post-transcriptional regulation and ER-chaperone-dependent trafficking; and the receptor plays defined roles in hippocampal inhibitory circuit maintenance, sperm motility, immune/inflammatory modulation via the cholinergic anti-inflammatory pathway, neural progenitor proliferation versus neuronal differentiation (via YAP1), and nicotine reward behavior."},"narrative":{"mechanistic_narrative":"CHRNA7 encodes the α7 subunit of a neuronal nicotinic acetylcholine receptor that functions as a calcium-permeable ligand-gated channel whose activation triggers intracellular signaling cascades across neural, immune, reproductive, and oncogenic contexts [PMID:29129316, PMID:40847805]. Functional receptor output is tightly gated by gene dosage: both haploinsufficiency and overexpression reduce α7-associated calcium flux, the latter through ER chaperone induction, ER stress, and failure to incorporate accumulated α7 subunits into surface receptors [PMID:29129316, PMID:34320968]. The human-specific partial duplicate CHRFAM7A co-assembles with α7 to form ACh-silent, non-conducting receptors that dominantly suppress channel function while retaining α-bungarotoxin binding [PMID:21718690]. CHRNA7 transcription is controlled by AP-2α-mediated repression of the proximal promoter and by inverse-correlated promoter DNA methylation, such that DNMT inhibition, methyl-donor depletion, or HDAC inhibitors de-repress expression [PMID:21979958, PMID:22052086, PMID:30974230]; long-range MeCP2-dependent chromatin interactions with the 15q11.2-13.3 PWS imprinting region provide additional transcriptional control lost upon neuronal differentiation [PMID:21840925]. Genetic determination of receptor level operates post-transcriptionally, affecting α-bungarotoxin-binding protein without changing RNA [PMID:19368846]. Downstream, ligand-activated α7 engages ERK1/2 for neuroprotection against oxidative stress, JAK2/STAT3 in anti-inflammatory signaling and cancer stem-cell maintenance, PI3K/Akt in tumor cell migration and apoptosis resistance, and YAP1 to drive radial glia proliferation at the expense of neuronal differentiation [PMID:28890319, PMID:29274273, PMID:33603170, PMID:26719016, PMID:bio_10.1101_2025.04.10.647795]. The receptor controls hippocampal inhibitory circuit composition (GAD, parvalbumin, GABAA subunits), sensory inhibition responsive to choline, sperm midpiece motility, nicotine reward behavior, and cholinergic anti-inflammatory cytokine suppression, and is acted upon by the endogenous ligand SLURP1 as a functional antagonist of nicotine [PMID:22314319, PMID:24462939, PMID:15944242, PMID:24289814, PMID:40847805, PMID:29545933].","teleology":[{"year":2005,"claim":"Establishing whether α7 nAChR has a peripheral physiological role beyond the brain, the sperm motility phenotype showed the receptor functions as an ionotropic regulator in non-neural cells.","evidence":"Chrna7 null mouse with CASA motility analysis and fluorescent α-bungarotoxin localization to the sperm midpiece","pmids":["15944242"],"confidence":"Medium","gaps":["Downstream signaling coupling Ca2+ to flagellar motility not defined","No human sperm confirmation","Whether CHRFAM7A modulates this peripheral function untested"]},{"year":2005,"claim":"Mapping how CHRNA7 transcription is embedded in the PWS/AS imprinting locus identified an intronic neuronal enhancer, framing the gene's tissue-specific regulation within a complex genomic region.","evidence":"TgPWS/TgAS transgenic mouse with mapped intron 4 breakpoint and quantitative tissue expression","pmids":["16280085"],"confidence":"Medium","gaps":["Enhancer not validated in isolation","Trans-acting factors binding the enhancer unknown","Human relevance of the murine breakpoint unclear"]},{"year":2009,"claim":"Resolving the level at which genetic variation sets receptor abundance, linkage analysis showed Chrna7 genotype controls α-bungarotoxin-binding protein but not RNA, pinpointing post-transcriptional regulation.","evidence":"F2 mouse mapping cross with parallel autoradiographic protein and in situ RNA quantitation","pmids":["19368846"],"confidence":"Medium","gaps":["Specific post-transcriptional mechanism (translation, assembly, trafficking) not identified","Causal variant not cloned"]},{"year":2011,"claim":"Defining the function of the human-specific duplicate, co-expression demonstrated CHRFAM7A forms ACh-silent receptors that dominantly suppress α7 channel function, explaining a uniquely human modulator of cholinergic signaling.","evidence":"Electrophysiology in cell lines and Xenopus oocytes, α-bungarotoxin binding, and PNU-120596 allosteric pharmacology","pmids":["21718690"],"confidence":"High","gaps":["Subunit stoichiometry of mixed receptors not resolved","In vivo contribution in human tissue not quantified"]},{"year":2011,"claim":"Identifying transcriptional and epigenetic control, AP-2α was shown to repress the proximal promoter and promoter DNA methylation was shown to inversely set expression, establishing two layers of CHRNA7 regulation.","evidence":"Promoter mutagenesis, ChIP/EMSA/supershift with AP-2α KD/OE; bisulfite sequencing, DNMT inhibitors, and methyl-donor manipulation","pmids":["21979958","22052086"],"confidence":"High","gaps":["Signals that recruit AP-2α or set methylation in vivo unknown","Interplay between the two mechanisms not dissected"]},{"year":2011,"claim":"Connecting CHRNA7 to neurodevelopmental disease regulation, MeCP2-dependent long-range chromatin contacts with the PWS imprinting center were shown to modulate transcription and to correlate with reduced expression in Rett and autism brain.","evidence":"4C chromatin conformation capture confirmed by FISH in neurons plus qRT-PCR in postmortem human cortex","pmids":["21840925"],"confidence":"Medium","gaps":["Causal direction between chromatin loop loss and expression not proven","Mechanism linking the loop to disease phenotype unestablished"]},{"year":2012,"claim":"Testing what circuit-level role α7 plays, dosage reduction was shown to lower hippocampal inhibitory components, indicating the receptor maintains inhibitory circuit composition.","evidence":"Quantitative immunoblotting of GAD-65 and GABAA receptors in Chrna7 heterozygous hippocampus","pmids":["22314319"],"confidence":"Medium","gaps":["Functional electrophysiological consequence not measured here","Cell-type origin of changes unresolved"]},{"year":2013,"claim":"Determining α7's role in addiction, bidirectional genetic and pharmacological manipulation showed Chrna7 constrains nicotine reward behavior.","evidence":"Chrna7 KO and gain-of-function mice in nicotine CPP with selective agonist/antagonist and nucleus accumbens expression profiling","pmids":["24289814"],"confidence":"Medium","gaps":["Circuit through which α7 limits reward not defined","Significance of accumbens insulin signaling change unclear"]},{"year":2014,"claim":"Extending the inhibitory-circuit and behavioral roles, graded genetic models showed dose- and sex-dependent GABAergic remodeling and demonstrated that choline-mediated improvement of sensory inhibition requires functional α7.","evidence":"WT/Het/KO immunoblotting for GABAA subunits, parvalbumin, GAD67; gestational choline supplementation with auditory sensory inhibition and hippocampal α-bungarotoxin binding","pmids":["24836856","24462939"],"confidence":"Medium","gaps":["Mechanism linking receptor level to subunit changes unknown","Developmental window of choline action not delimited"]},{"year":2017,"claim":"Mapping downstream effectors, distinct studies established that ligand-activated α7 signals through ERK1/2 for neuroprotection and through JAK2/STAT3 for anti-inflammatory neuroprotection and cancer stem-cell maintenance.","evidence":"siRNA knockdown in SH-SY5Y with ERK1/2 readout; rat PMCAO with VNS and α7 agonist/antagonist measuring p-JAK2/p-STAT3; ESCC cells/xenografts with JAK2/STAT3 and promoter methylation analysis","pmids":["28890319","29274273","33603170"],"confidence":"Medium","gaps":["Direct biochemical link from channel to each kinase cascade not shown","Cell-type specificity of pathway selection unresolved"]},{"year":2017,"claim":"Clarifying why gene dosage gain is deleterious, iPSC neural progenitors with 15q13.3 duplication revealed that overexpression induces ER chaperones and ER stress, trapping α7 subunits and reducing calcium flux just as haploinsufficiency does.","evidence":"iPSC-derived NPCs from deletion and duplication carriers with calcium flux, chaperone transcriptomics, and ER stress markers","pmids":["29129316"],"confidence":"High","gaps":["Identity of chaperones limiting assembly not pinned down","Whether CHRFAM7A contributes to the duplication phenotype not isolated"]},{"year":2018,"claim":"Identifying an endogenous physiological ligand, SLURP1 was shown to act through CHRNA7 as a functional antagonist of nicotine with opposing anti-malignant effects.","evidence":"SLURP1 and nicotine treatment of CHRNA7-high PDAC cells with binding and downstream signaling analysis","pmids":["29545933"],"confidence":"Low","gaps":["No defined binding affinity or structural interaction","CHRNA7-dependence shown without knockdown rescue across all readouts"]},{"year":2019,"claim":"Refining epigenetic control, promoter methylation across multiple regions was shown to be pharmacologically reversible by valproate with corresponding expression gains, reinforcing methylation as a tunable regulatory switch.","evidence":"Bisulfite pyrosequencing of human cortex and cell lines with valproate treatment and qRT-PCR","pmids":["30974230"],"confidence":"Medium","gaps":["Direct versus HDAC-mediated effect of valproate not separated","Genotype-methylation causality not established"]},{"year":2020,"claim":"Demonstrating that expression and trafficking can be simultaneously enhanced therapeutically, lonafarnib was shown to de-repress CHRNA7 via Ras-c-Jun-JNK/DNMT1 and to boost membrane trafficking via CaMKII, increasing ACh-evoked currents and memory.","evidence":"In vivo mouse lonafarnib with CA1 patch-clamp, DNMT1/JNK/c-Jun immunoblotting, membrane fractionation, and pathway pharmacology","pmids":["33447242"],"confidence":"Medium","gaps":["Whether transcriptional and trafficking effects are mechanistically independent in vivo not fully separated","Off-target farnesylation effects not excluded"]},{"year":2021,"claim":"Establishing the developmental consequence of duplication in patient cells, iPSC cortical neurons showed CHRNA7 duplication enhances progenitor proliferation while impairing differentiation, maturation, and migration alongside ER stress.","evidence":"iPSC-derived neurons from proband, unaffected mother, and controls with electrophysiology, migration assay, scRNAseq, ER stress markers, and pharmacological rescue","pmids":["34320968"],"confidence":"High","gaps":["Why proband and unaffected mother diverge phenotypically not resolved","Effector linking channel activity to migration deficit not identified here"]},{"year":2025,"claim":"Identifying the proliferation-versus-differentiation effector, nAChR signaling in human radial glia was shown to act through YAP1 to favor proliferation, with CHRNA7 and CHRFAM7A driving distinct transcriptional responses to nicotine.","evidence":"Human cortical organotypic and dissociated cultures with nAChR activation/knockdown, scRNAseq, and YAP1 inhibitor rescue (preprint)","pmids":["bio_10.1101_2025.04.10.647795"],"confidence":"Medium","gaps":["Preprint, not yet peer-reviewed","Biochemical link from channel Ca2+ to YAP1 activation not defined","Divergence of CHRNA7 versus CHRFAM7A transcriptional programs not mechanistically explained"]},{"year":null,"claim":"How the diverse downstream cascades (ERK1/2, JAK2/STAT3, PI3K/Akt, YAP1) are selected by α7 channel activity in different cell types, and how CHRFAM7A and ER-chaperone trafficking quantitatively tune surface receptor output in human tissue, remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model linking channel gating to pathway choice","Quantitative contribution of CHRFAM7A to native human receptor pools unmeasured","Identity of the ER chaperones limiting assembly not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,23]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,4,17]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[1,19]}],"pathway":[{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[5,6,7,17]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[8,9,10,12]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[10,22,23]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,3,15,16]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[19,20]}],"complexes":["α7 homopentameric nicotinic acetylcholine receptor","α7/CHRFAM7A heteromeric (non-conducting) receptor"],"partners":["CHRFAM7A","SLURP1","AP-2Α","MECP2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P36544","full_name":"Neuronal acetylcholine receptor subunit alpha-7","aliases":["Nicotinic acetylcholine receptor subunit alpha-7"],"length_aa":502,"mass_kda":56.4,"function":"Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction. Each nAchR subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, cation permeability, and binding to allosteric modulators (PubMed:15609996, PubMed:33735609, PubMed:8145738). CHRNA7 forms homopentameric neuronal acetylcholine receptors abundantly expressed in the central nervous system, characterized by fast desensitization and high calcium permeability (PubMed:31560909, PubMed:33735609, PubMed:38382524, PubMed:8145738). Also forms heteropentamers with CHRNB2, mainly expressed in basal forebrain cholinergic neurons. Involved in the modulation of calcium-dependent signaling pathways and influences the release of neurotransmitters, including dopamine, glutamate and GABA (PubMed:33239400). Also expressed in non-neuronal cells such as immune cells like lymphocytes, monocytes and macrophages (PubMed:12508119, PubMed:16968406, PubMed:25259522). In T cells, activation induces metabotropic signaling that results in an increase of intracellular Ca2+ concentrations, independent of ionotropic receptor functions (PubMed:17709503). In macrophages, required for acetylcholine-mediated inhibition of TNF and other inflammatory cytokine release (PubMed:12508119). Once activated by acetylcholine, nicotine or other agonists, selectively inhibits production of pro-inflammatory cytokines while leaving anti-inflammatory cytokines undisturbed (PubMed:12508119, PubMed:25259522). Stimulates the cholinergic anti-inflammatory pathway, controlling inflammation by inhibiting NFKB nuclear translocation and activating the JAK2-STAT3 pathway, independently of ion channel activity (PubMed:16968406, PubMed:25259522). Also expressed in the urothelium where it modulates reflex bladder activity by increasing intracellular calcium through internal stores and decreasing basal ATP release (By similarity)","subcellular_location":"Postsynaptic cell membrane; Cell membrane","url":"https://www.uniprot.org/uniprotkb/P36544/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CHRNA7","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CHRNA7","total_profiled":1310},"omim":[{"mim_id":"613025","title":"SCHIZOPHRENIA 13; SCZD13","url":"https://www.omim.org/entry/613025"},{"mim_id":"612024","title":"OTU DOMAIN-CONTAINING PROTEIN 7A; OTUD7A","url":"https://www.omim.org/entry/612024"},{"mim_id":"612001","title":"CHROMOSOME 15q13.3 DELETION SYNDROME","url":"https://www.omim.org/entry/612001"},{"mim_id":"610509","title":"RIC3 ACETYLCHOLINE RECEPTOR CHAPERONE; RIC3","url":"https://www.omim.org/entry/610509"},{"mim_id":"609756","title":"CHRNA7/FAM7A FUSION GENE; CHRFAM7A","url":"https://www.omim.org/entry/609756"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adrenal gland","ntpm":7.3},{"tissue":"intestine","ntpm":9.1}],"url":"https://www.proteinatlas.org/search/CHRNA7"},"hgnc":{"alias_symbol":["a7nAChR"],"prev_symbol":[]},"alphafold":{"accession":"P36544","domains":[{"cath_id":"2.70.170.10","chopping":"22-228","consensus_level":"high","plddt":91.8307,"start":22,"end":228},{"cath_id":"1.20.58.390","chopping":"232-340_468-500","consensus_level":"high","plddt":83.6222,"start":232,"end":500}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P36544","model_url":"https://alphafold.ebi.ac.uk/files/AF-P36544-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P36544-F1-predicted_aligned_error_v6.png","plddt_mean":78.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CHRNA7","jax_strain_url":"https://www.jax.org/strain/search?query=CHRNA7"},"sequence":{"accession":"P36544","fasta_url":"https://rest.uniprot.org/uniprotkb/P36544.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P36544/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P36544"}},"corpus_meta":[{"pmid":"9782083","id":"PMC_9782083","title":"Genomic organization and partial duplication of the human alpha7 neuronal nicotinic acetylcholine receptor gene (CHRNA7).","date":"1998","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9782083","citation_count":218,"is_preprint":false},{"pmid":"11424985","id":"PMC_11424985","title":"Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha7-nicotinic acetylcholine receptor subunit gene (CHRNA7).","date":"2001","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11424985","citation_count":161,"is_preprint":false},{"pmid":"25701707","id":"PMC_25701707","title":"The human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and function.","date":"2015","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25701707","citation_count":147,"is_preprint":false},{"pmid":"33422641","id":"PMC_33422641","title":"A role of the subdiaphragmatic vagus nerve in depression-like phenotypes in mice after fecal microbiota transplantation from Chrna7 knock-out mice with depression-like phenotypes.","date":"2021","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/33422641","citation_count":147,"is_preprint":false},{"pmid":"17978319","id":"PMC_17978319","title":"Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use.","date":"2007","source":"The British journal of psychiatry : the journal of mental science","url":"https://pubmed.ncbi.nlm.nih.gov/17978319","citation_count":124,"is_preprint":false},{"pmid":"20506139","id":"PMC_20506139","title":"Structures and molecular mechanisms for common 15q13.3 microduplications involving CHRNA7: benign or pathological?","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/20506139","citation_count":112,"is_preprint":false},{"pmid":"21718690","id":"PMC_21718690","title":"The chimeric gene CHRFAM7A, a partial duplication of the CHRNA7 gene, is a dominant negative regulator of α7*nAChR function.","date":"2011","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21718690","citation_count":111,"is_preprint":false},{"pmid":"11829490","id":"PMC_11829490","title":"A 3-Mb map of a large Segmental duplication overlapping the alpha7-nicotinic acetylcholine receptor gene (CHRNA7) at human 15q13-q14.","date":"2002","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/11829490","citation_count":99,"is_preprint":false},{"pmid":"26095975","id":"PMC_26095975","title":"The human clinical phenotypes of altered CHRNA7 copy number.","date":"2015","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26095975","citation_count":96,"is_preprint":false},{"pmid":"10893497","id":"PMC_10893497","title":"Haplotype transmission disequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in Southern African Bantu families.","date":"2000","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10893497","citation_count":95,"is_preprint":false},{"pmid":"22775350","id":"PMC_22775350","title":"Identification of single gene deletions at 15q13.3: further evidence that CHRNA7 causes the 15q13.3 microdeletion syndrome phenotype.","date":"2012","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22775350","citation_count":88,"is_preprint":false},{"pmid":"19181484","id":"PMC_19181484","title":"Association of the 5'-upstream regulatory region of the alpha7 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia.","date":"2009","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/19181484","citation_count":86,"is_preprint":false},{"pmid":"8188270","id":"PMC_8188270","title":"Molecular cloning and chromosomal localization of the human alpha 7-nicotinic receptor subunit gene (CHRNA7).","date":"1994","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8188270","citation_count":82,"is_preprint":false},{"pmid":"21840925","id":"PMC_21840925","title":"15q11.2-13.3 chromatin analysis reveals epigenetic regulation of CHRNA7 with deficiencies in Rett and autism brain.","date":"2011","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21840925","citation_count":80,"is_preprint":false},{"pmid":"19680823","id":"PMC_19680823","title":"Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers.","date":"2009","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/19680823","citation_count":79,"is_preprint":false},{"pmid":"26651393","id":"PMC_26651393","title":"Perinatal Phosphatidylcholine Supplementation and Early Childhood Behavior Problems: Evidence for CHRNA7 Moderation.","date":"2015","source":"The American journal of psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/26651393","citation_count":74,"is_preprint":false},{"pmid":"11803513","id":"PMC_11803513","title":"Evidence for linkage disequilibrium between the alpha 7-nicotinic receptor gene (CHRNA7) locus and schizophrenia in Azorean families.","date":"2001","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11803513","citation_count":65,"is_preprint":false},{"pmid":"15944242","id":"PMC_15944242","title":"Mice deficient in CHRNA7, a subunit of the nicotinic acetylcholine receptor, produce sperm with impaired motility.","date":"2005","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/15944242","citation_count":62,"is_preprint":false},{"pmid":"27853923","id":"PMC_27853923","title":"The Cognitive and Behavioral Phenotypes of Individuals with CHRNA7 Duplications.","date":"2017","source":"Journal of autism and developmental disorders","url":"https://pubmed.ncbi.nlm.nih.gov/27853923","citation_count":57,"is_preprint":false},{"pmid":"23350639","id":"PMC_23350639","title":"Dysfunction of SHANK2 and CHRNA7 in a patient with intellectual disability and language impairment supports genetic epistasis of the two loci.","date":"2013","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23350639","citation_count":57,"is_preprint":false},{"pmid":"29274273","id":"PMC_29274273","title":"Nicotinic Acetylcholine Receptor Alpha7 Subunit Mediates Vagus Nerve Stimulation-Induced Neuroprotection in Acute Permanent Cerebral Ischemia by a7nAchR/JAK2 Pathway.","date":"2017","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/29274273","citation_count":53,"is_preprint":false},{"pmid":"18078695","id":"PMC_18078695","title":"APOE, ACT and CHRNA7 genes in the conversion from amnestic mild cognitive impairment to Alzheimer's disease.","date":"2007","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/18078695","citation_count":53,"is_preprint":false},{"pmid":"9754620","id":"PMC_9754620","title":"No evidence for linkage of the CHRNA7 gene region in Canadian schizophrenia families.","date":"1998","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9754620","citation_count":51,"is_preprint":false},{"pmid":"20425840","id":"PMC_20425840","title":"A 15q13.3 homozygous microdeletion associated with a severe neurodevelopmental disorder suggests putative functions of the TRPM1, CHRNA7, and other homozygously deleted genes.","date":"2010","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/20425840","citation_count":47,"is_preprint":false},{"pmid":"36191806","id":"PMC_36191806","title":"A role of gut-microbiota-brain axis via subdiaphragmatic vagus nerve in depression-like phenotypes in Chrna7 knock-out mice.","date":"2022","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/36191806","citation_count":46,"is_preprint":false},{"pmid":"29129316","id":"PMC_29129316","title":"Functional Consequences of CHRNA7 Copy-Number Alterations in Induced Pluripotent Stem Cells and Neural Progenitor Cells.","date":"2017","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29129316","citation_count":44,"is_preprint":false},{"pmid":"25655306","id":"PMC_25655306","title":"Analysis of CHRNA7 rare variants in autism spectrum disorder susceptibility.","date":"2015","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/25655306","citation_count":43,"is_preprint":false},{"pmid":"21596161","id":"PMC_21596161","title":"Homozygous deletion of chromosome 15q13.3 including CHRNA7 causes severe mental retardation, seizures, muscular hypotonia, and the loss of KLF13 and TRPM1 potentially cause macrocytosis and congenital retinal dysfunction in siblings.","date":"2011","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21596161","citation_count":43,"is_preprint":false},{"pmid":"12049804","id":"PMC_12049804","title":"Evaluation of the positional candidate gene CHRNA7 at the juvenile myoclonic epilepsy locus (EJM2) on chromosome 15q13-14.","date":"2002","source":"Epilepsy research","url":"https://pubmed.ncbi.nlm.nih.gov/12049804","citation_count":42,"is_preprint":false},{"pmid":"22314319","id":"PMC_22314319","title":"Reduced Chrna7 expression in mice is associated with decreases in hippocampal markers of inhibitory function: implications for neuropsychiatric diseases.","date":"2012","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/22314319","citation_count":37,"is_preprint":false},{"pmid":"21990074","id":"PMC_21990074","title":"A small homozygous microdeletion of 15q13.3 including the CHRNA7 gene in a girl with a spectrum of severe neurodevelopmental features.","date":"2011","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/21990074","citation_count":37,"is_preprint":false},{"pmid":"28045139","id":"PMC_28045139","title":"Chrna7 deficient mice manifest no consistent neuropsychiatric and behavioral phenotypes.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28045139","citation_count":35,"is_preprint":false},{"pmid":"31048268","id":"PMC_31048268","title":"Effect of donepezil on the expression and responsiveness to LPS of CHRNA7 and CHRFAM7A in macrophages: A possible link to the cholinergic anti-inflammatory pathway.","date":"2019","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/31048268","citation_count":35,"is_preprint":false},{"pmid":"24424125","id":"PMC_24424125","title":"CHRNA7 triplication associated with cognitive impairment and neuropsychiatric phenotypes in a three-generation pedigree.","date":"2014","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/24424125","citation_count":35,"is_preprint":false},{"pmid":"33603170","id":"PMC_33603170","title":"Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33603170","citation_count":33,"is_preprint":false},{"pmid":"24155726","id":"PMC_24155726","title":"Association of the Nicotinic Receptor α7 Subunit Gene (CHRNA7) with Schizophrenia and Visual Backward Masking.","date":"2013","source":"Frontiers in psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/24155726","citation_count":33,"is_preprint":false},{"pmid":"24391883","id":"PMC_24391883","title":"CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer's disease.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24391883","citation_count":29,"is_preprint":false},{"pmid":"24951635","id":"PMC_24951635","title":"Effect of APOE and CHRNA7 genotypes on the cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.","date":"2014","source":"American journal of Alzheimer's disease and other dementias","url":"https://pubmed.ncbi.nlm.nih.gov/24951635","citation_count":28,"is_preprint":false},{"pmid":"10439438","id":"PMC_10439438","title":"Localization of mRNA for CHRNA7 in human fetal brain.","date":"1999","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/10439438","citation_count":28,"is_preprint":false},{"pmid":"27061851","id":"PMC_27061851","title":"An acetylcholine alpha7 positive allosteric modulator rescues a schizophrenia-associated brain endophenotype in the 15q13.3 microdeletion, encompassing CHRNA7.","date":"2016","source":"European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27061851","citation_count":27,"is_preprint":false},{"pmid":"24289814","id":"PMC_24289814","title":"Genetic variation within the Chrna7 gene modulates nicotine reward-like phenotypes in mice.","date":"2013","source":"Genes, brain, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/24289814","citation_count":26,"is_preprint":false},{"pmid":"29545933","id":"PMC_29545933","title":"Endogenous CHRNA7-ligand SLURP1 as a potential tumor suppressor and anti-nicotinic factor in pancreatic cancer.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29545933","citation_count":25,"is_preprint":false},{"pmid":"26424395","id":"PMC_26424395","title":"Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitors (AChEI) in Patients with Alzheimer's Disease.","date":"2017","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/26424395","citation_count":24,"is_preprint":false},{"pmid":"24462939","id":"PMC_24462939","title":"Long-term improvements in sensory inhibition with gestational choline supplementation linked to α7 nicotinic receptors through studies in Chrna7 null mutation mice.","date":"2014","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/24462939","citation_count":23,"is_preprint":false},{"pmid":"11803515","id":"PMC_11803515","title":"No association between CHRNA7 microsatellite markers and attention-deficit hyperactivity disorder.","date":"2001","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11803515","citation_count":22,"is_preprint":false},{"pmid":"21294583","id":"PMC_21294583","title":"In search of allosteric modulators of a7-nAChR by solvent density guided virtual screening.","date":"2011","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/21294583","citation_count":21,"is_preprint":false},{"pmid":"26567012","id":"PMC_26567012","title":"Expression of CHRFAM7A and CHRNA7 in neuronal cells and postmortem brain of HIV-infected patients: considerations for HIV-associated neurocognitive disorder.","date":"2015","source":"Journal of neurovirology","url":"https://pubmed.ncbi.nlm.nih.gov/26567012","citation_count":19,"is_preprint":false},{"pmid":"20463630","id":"PMC_20463630","title":"Evidence for association of the non-duplicated region of CHRNA7 gene with bipolar disorder but not with Schizophrenia.","date":"2010","source":"Psychiatric genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20463630","citation_count":19,"is_preprint":false},{"pmid":"17113175","id":"PMC_17113175","title":"Linkage disequilibrium analysis of the CHRNA7 gene and its partially duplicated region in schizophrenia.","date":"2006","source":"Neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/17113175","citation_count":18,"is_preprint":false},{"pmid":"27104904","id":"PMC_27104904","title":"CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimer's Disease Patients.","date":"2016","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/27104904","citation_count":18,"is_preprint":false},{"pmid":"29666375","id":"PMC_29666375","title":"Association and cis-mQTL analysis of variants in CHRNA3-A5, CHRNA7, CHRNB2, and CHRNB4 in relation to nicotine dependence in a Chinese Han population.","date":"2018","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/29666375","citation_count":18,"is_preprint":false},{"pmid":"26376812","id":"PMC_26376812","title":"Association Study of CHRNA7 Promoter Variants with Sensory and Sensorimotor Gating in Schizophrenia Patients and Healthy Controls: A Danish Case-Control Study.","date":"2015","source":"Neuromolecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26376812","citation_count":18,"is_preprint":false},{"pmid":"27249957","id":"PMC_27249957","title":"CHRNA7 Polymorphisms and Dementia Risk: Interactions with Apolipoprotein ε4 and Cigarette Smoking.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27249957","citation_count":17,"is_preprint":false},{"pmid":"21550667","id":"PMC_21550667","title":"CHRNA7 haplotypes are associated with impaired attention in euthymic bipolar disorder.","date":"2011","source":"Journal of affective disorders","url":"https://pubmed.ncbi.nlm.nih.gov/21550667","citation_count":17,"is_preprint":false},{"pmid":"34320968","id":"PMC_34320968","title":"Altered neuronal physiology, development, and function associated with a common chromosome 15 duplication involving CHRNA7.","date":"2021","source":"BMC biology","url":"https://pubmed.ncbi.nlm.nih.gov/34320968","citation_count":15,"is_preprint":false},{"pmid":"26790437","id":"PMC_26790437","title":"Silencing A7-nAChR levels increases the sensitivity of gastric cancer cells to ixabepilone treatment.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26790437","citation_count":15,"is_preprint":false},{"pmid":"22300029","id":"PMC_22300029","title":"Genetic variations in CHRNA7 or CHRFAM7 and susceptibility to dementia.","date":"2012","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/22300029","citation_count":14,"is_preprint":false},{"pmid":"26719016","id":"PMC_26719016","title":"CHRNA7 inhibits cell invasion and metastasis of LoVo human colorectal cancer cells through PI3K/Akt signaling.","date":"2015","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/26719016","citation_count":14,"is_preprint":false},{"pmid":"22052086","id":"PMC_22052086","title":"Promoter methylation and tissue-specific transcription of the α7 nicotinic receptor gene, CHRNA7.","date":"2011","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/22052086","citation_count":14,"is_preprint":false},{"pmid":"31352702","id":"PMC_31352702","title":"Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for CACNA1C, CHRNA7 and MAPK1.","date":"2019","source":"Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31352702","citation_count":14,"is_preprint":false},{"pmid":"20927308","id":"PMC_20927308","title":"Genetic Association Study of the Alpha 7 Nicotinic Receptor (CHRNA7) with the Development of Schizophrenia and Bipolar Disorder in Korean Population.","date":"2010","source":"Psychiatry investigation","url":"https://pubmed.ncbi.nlm.nih.gov/20927308","citation_count":14,"is_preprint":false},{"pmid":"21979958","id":"PMC_21979958","title":"Transcriptional repression of the α7 nicotinic acetylcholine receptor subunit gene (CHRNA7) by activating protein-2α (AP-2α).","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21979958","citation_count":13,"is_preprint":false},{"pmid":"30029151","id":"PMC_30029151","title":"CHRNA7 copy number gains are enriched in adolescents with major depressive and anxiety disorders.","date":"2018","source":"Journal of affective disorders","url":"https://pubmed.ncbi.nlm.nih.gov/30029151","citation_count":13,"is_preprint":false},{"pmid":"16280085","id":"PMC_16280085","title":"Genetic mapping of putative Chrna7 and Luzp2 neuronal transcriptional enhancers due to impact of a transgene-insertion and 6.8 Mb deletion in a mouse model of Prader-Willi and Angelman syndromes.","date":"2005","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/16280085","citation_count":13,"is_preprint":false},{"pmid":"22981153","id":"PMC_22981153","title":"No effect of polymorphisms in the non-duplicated region of the CHRNA7 gene on sensory gating P50 ratios in patients with schizophrenia and bipolar disorder.","date":"2012","source":"Psychiatry research","url":"https://pubmed.ncbi.nlm.nih.gov/22981153","citation_count":13,"is_preprint":false},{"pmid":"24836856","id":"PMC_24836856","title":"Reduced CHRNA7 expression in C3H mice is associated with increases in hippocampal parvalbumin and glutamate decarboxylase-67 (GAD67) as well as altered levels of GABA(A) receptor subunits.","date":"2014","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24836856","citation_count":12,"is_preprint":false},{"pmid":"30089821","id":"PMC_30089821","title":"Genetic variation in CHRNA7 and CHRFAM7A is associated with nicotine dependence and response to varenicline treatment.","date":"2018","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/30089821","citation_count":11,"is_preprint":false},{"pmid":"28817303","id":"PMC_28817303","title":"CHRNA7 Deletions are Enriched in Risperidone-Treated Children and Adolescents.","date":"2017","source":"Journal of child and adolescent psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28817303","citation_count":10,"is_preprint":false},{"pmid":"38944290","id":"PMC_38944290","title":"Splenic nerve denervation attenuates depression-like behaviors in Chrna7 knock-out mice via the spleen-gut-brain axis.","date":"2024","source":"Journal of affective disorders","url":"https://pubmed.ncbi.nlm.nih.gov/38944290","citation_count":10,"is_preprint":false},{"pmid":"35344211","id":"PMC_35344211","title":"Polymorphisms in alpha 7 nicotinic acetylcholine receptor gene, CHRNA7, and its partially duplicated gene, CHRFAM7A, associate with increased inflammatory response in human peripheral mononuclear cells.","date":"2022","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/35344211","citation_count":9,"is_preprint":false},{"pmid":"23454271","id":"PMC_23454271","title":"Mosaic 15q13.3 deletion including CHRNA7 gene in monozygotic twins.","date":"2013","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23454271","citation_count":9,"is_preprint":false},{"pmid":"30974230","id":"PMC_30974230","title":"DNA methylation regulates CHRNA7 transcription and can be modulated by valproate.","date":"2019","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/30974230","citation_count":8,"is_preprint":false},{"pmid":"28867899","id":"PMC_28867899","title":"Homology Modeling and Protein Interaction Map of CHRNA7 Neurogenesis Protein.","date":"2017","source":"Annals of neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/28867899","citation_count":8,"is_preprint":false},{"pmid":"35111269","id":"PMC_35111269","title":"The Natural Compound Dehydrocrenatidine Attenuates Nicotine-Induced Stemness and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma by Regulating a7nAChR-Jak2 Signaling Pathways.","date":"2022","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/35111269","citation_count":7,"is_preprint":false},{"pmid":"19368846","id":"PMC_19368846","title":"Chrna7 genotype is linked with alpha7 nicotinic receptor expression but not alpha7 RNA levels.","date":"2009","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/19368846","citation_count":7,"is_preprint":false},{"pmid":"27109789","id":"PMC_27109789","title":"Cholinergic modulation of auditory P3 event-related potentials as indexed by CHRNA4 and CHRNA7 genotype variation in healthy volunteers.","date":"2016","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/27109789","citation_count":7,"is_preprint":false},{"pmid":"36604774","id":"PMC_36604774","title":"The holistic approach to the CHRNA7 gene, hsa-miR-3158-5p, and 15q13.3 hotspot CNVs in migraineurs.","date":"2023","source":"Molecular pain","url":"https://pubmed.ncbi.nlm.nih.gov/36604774","citation_count":6,"is_preprint":false},{"pmid":"38198758","id":"PMC_38198758","title":"The Prenatal Hypoxic Pathology Associated with Maternal Stress Predisposes to Dysregulated Expression of the chrna7 Gene and the Subsequent Development of Nicotine Addiction in Adult Offspring.","date":"2024","source":"Neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/38198758","citation_count":6,"is_preprint":false},{"pmid":"33447242","id":"PMC_33447242","title":"Farnesyl Transferase Inhibitor Lonafarnib Enhances α7nAChR Expression Through Inhibiting DNA Methylation of CHRNA7 and Increases α7nAChR Membrane Trafficking.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33447242","citation_count":6,"is_preprint":false},{"pmid":"28890319","id":"PMC_28890319","title":"Arctic Aβ40 blocks the nicotine-induced neuroprotective effect of CHRNA7 by inhibiting the ERK1/2 pathway in human neuroblastoma cells.","date":"2017","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/28890319","citation_count":6,"is_preprint":false},{"pmid":"37569633","id":"PMC_37569633","title":"GTS-21 Enhances Regulatory T Cell Development from T Cell Receptor-Activated Human CD4+ T Cells Exhibiting Varied Levels of CHRNA7 and CHRFAM7A Expression.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37569633","citation_count":5,"is_preprint":false},{"pmid":"34563047","id":"PMC_34563047","title":"Screening for Copy Number Variations of the 15q13.3 Hotspot in CHRNA7 Gene and Expression in Patients with Migraines.","date":"2021","source":"Current issues in molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/34563047","citation_count":5,"is_preprint":false},{"pmid":"28503599","id":"PMC_28503599","title":"Is Chromosome 15q13.3 Duplication Involving CHRNA7 Associated With Oral Clefts?","date":"2015","source":"Child neurology open","url":"https://pubmed.ncbi.nlm.nih.gov/28503599","citation_count":5,"is_preprint":false},{"pmid":"26722551","id":"PMC_26722551","title":"Effects of a7nAChR agonist on the tissue estrogen receptor expression of castrated rats.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26722551","citation_count":4,"is_preprint":false},{"pmid":"36831101","id":"PMC_36831101","title":"Effects of Different Exercise Types on Chrna7 and Chrfam7a Expression in Healthy Normal Weight and Overweight Type 2 Diabetic Adults.","date":"2023","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/36831101","citation_count":2,"is_preprint":false},{"pmid":"39722318","id":"PMC_39722318","title":"Sinomenine modulates the metabolic reprogramming induced by sepsis via CHRNA7.","date":"2024","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39722318","citation_count":2,"is_preprint":false},{"pmid":"30218896","id":"PMC_30218896","title":"Copy number variations in healthy subjects. Case study: iPSC line CSSi005-A (3544) production from an individual with variation in 15q13.3 chromosome duplicating gene CHRNA7.","date":"2018","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/30218896","citation_count":2,"is_preprint":false},{"pmid":"39647824","id":"PMC_39647824","title":"Prenatal Hypoxia Predisposes to Impaired Expression of the chrna4 and chrna7 Genes in Adult Rats without Affecting Acetylcholine Metabolism during Embryonic Development.","date":"2024","source":"Biochemistry. Biokhimiia","url":"https://pubmed.ncbi.nlm.nih.gov/39647824","citation_count":1,"is_preprint":false},{"pmid":"39559484","id":"PMC_39559484","title":"Electroacupuncture alleviates paradoxical sleep deprivation-induced postoperative hyperalgesia via a7nAChR mediated BDNF/TrkB-KCC2 signaling pathway in the spinal cord.","date":"2024","source":"IBRO neuroscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/39559484","citation_count":1,"is_preprint":false},{"pmid":"40049827","id":"PMC_40049827","title":"Genetic counseling of prenatally detected familial 15q13.2q13.3 microdeletion encompassing CHRNA7 and OTUD7A with asymptomatic carriers in the family.","date":"2025","source":"Taiwanese journal of obstetrics & gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/40049827","citation_count":1,"is_preprint":false},{"pmid":"25975508","id":"PMC_25975508","title":"Analysis of the CHRNA7 gene mutation and polymorphism in Southern Han Chinese patients with nocturnal frontal epilepsy.","date":"2015","source":"Asian Pacific journal of tropical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25975508","citation_count":1,"is_preprint":false},{"pmid":"33884253","id":"PMC_33884253","title":"Rapid-Onset Obesity Due to Impulsive Food-Seeking Behavior in a Puerto Rican Child With CHRNA7 15q13.3 Microdeletion.","date":"2021","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/33884253","citation_count":1,"is_preprint":false},{"pmid":"40419554","id":"PMC_40419554","title":"Intestinal microbiota improves inflammation and cognitive function in the brain of a7nAChR deficient rat through the gut brain axis.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/40419554","citation_count":0,"is_preprint":false},{"pmid":"40847805","id":"PMC_40847805","title":"Activation of the alpha 7 nicotinic acetylcholine receptor (CHRNA7) limits hypoxia-induced inflammatory responses and regulates collagens in cultured human granulosa cells†.","date":"2026","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/40847805","citation_count":0,"is_preprint":false},{"pmid":"41663888","id":"PMC_41663888","title":"Signal-Level Determinants of Cognitive Decline With PPIs versus H2RAs: Transportome (CBLIF/TCN2) and CHRNA7 Nodes.","date":"2026","source":"Molecular nutrition & food research","url":"https://pubmed.ncbi.nlm.nih.gov/41663888","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.04.10.647795","title":"α7 nicotinic acetylcholine receptors regulate radial glia fate in the developing human cortex","date":"2025-04-10","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.10.647795","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50307,"output_tokens":6837,"usd":0.126738,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16136,"output_tokens":5539,"usd":0.109577,"stage2_stop_reason":"end_turn"},"total_usd":0.236315,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"CHRFAM7A (the partial duplication of CHRNA7) acts as a dominant negative regulator of α7*nAChR function. Co-expression of α7 and CHRFAM7A in cell lines and Xenopus oocytes caused significant reduction of ACh-evoked current amplitude without reducing α-bungarotoxin binding, indicating formation of non-functional (ACh-silent) receptors. The allosteric modulator PNU-120596 produced a larger increase in ACh-evoked current in cells co-expressing the duplicate, consistent with a population of closed, non-conducting α7 receptors.\",\n      \"method\": \"Functional electrophysiology (ACh-evoked currents) in cell lines and Xenopus oocytes; radioligand binding with [125I]-α-bungarotoxin; allosteric modulator pharmacology\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution in heterologous expression systems (cell lines + Xenopus oocytes), multiple orthogonal functional and binding assays in one rigorous study\",\n      \"pmids\": [\"21718690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In iPSC-derived neural progenitor cells from individuals with 15q13.3 duplications, increased CHRNA7 mRNA expression is associated with higher expression of nAChR-specific and resident ER chaperones, indicating increased ER stress and inefficient receptor assembly, resulting in accumulation of α7 subunits in the ER rather than incorporation into functional cell-surface receptors. Both deletions (haploinsufficiency) and duplications (ER stress/trafficking failure) lead to decreased α7 nAChR-associated calcium flux.\",\n      \"method\": \"iPSC-derived neural progenitor cells from human subjects with deletions and duplications; calcium flux assay; mRNA expression analysis of chaperones; ER stress markers\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — human iPSC/NPC model with multiple orthogonal methods (Ca2+ flux, transcriptomics, chaperone analysis), single lab but mechanistically rigorous\",\n      \"pmids\": [\"29129316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CHRNA7 transcription is repressed by the transcription factor AP-2α. A 230-bp proximal promoter fragment necessary for transcription in neuroblastoma cells contains a functional AP-2α binding site; mutation of this site, AP-2α knockdown, and AP-2α overexpression all modulate CHRNA7 transcription. AP-2α binding was confirmed by EMSA, supershift assay, and chromatin immunoprecipitation.\",\n      \"method\": \"Promoter mutagenesis; AP-2α knockdown and overexpression; EMSA; supershift assay; chromatin immunoprecipitation (ChIP); reporter assay in neuroblastoma cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (mutagenesis, ChIP, EMSA, supershift, KD/OE) in one rigorous study\",\n      \"pmids\": [\"21979958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"DNA methylation of the CHRNA7 proximal promoter inversely correlates with CHRNA7 mRNA expression across human tissue types and cell lines. Treatment with DNA methyltransferase inhibitors (5-aza-2-deoxycytidine, zebularine) restored or increased CHRNA7 expression in cells with hypermethylated promoters, while removal of the methyl donor methionine increased transcription. Bisulfite sequencing confirmed hypermethylation of the proximal promoter in silenced cells.\",\n      \"method\": \"Bisulfite sequencing PCR; methylation-sensitive restriction enzyme analysis (MSRE); DNMT inhibitor treatment; methyl donor manipulation; qRT-PCR across multiple human tissue types\",\n      \"journal\": \"Journal of molecular neuroscience : MN\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal epigenetic methods (bisulfite sequencing, MSRE, pharmacological inhibition, methyl donor manipulation) across multiple tissue types in a single rigorous study\",\n      \"pmids\": [\"22052086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Chrna7 knock-out mice display significantly impaired sperm motility characterized by reduced swimming velocities, failure to maintain vigorous swimming, and lower levels of hyperactivated swimming, with no differences in sperm number, morphology, viability, or spontaneous acrosome reaction rate. Fluorescent α-bungarotoxin localized nAChR binding sites (primarily CHRNA7) to the midpiece of sperm, suggesting an ionotropic role in motility.\",\n      \"method\": \"Chrna7 null mouse genetic model; computer-assisted sperm analysis (CASA); fluorescent α-bungarotoxin-TRITC binding localization; immunoblot; RT-PCR\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO mouse with defined motility phenotype and receptor localization data, single lab with multiple methods\",\n      \"pmids\": [\"15944242\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Reduced Chrna7 expression in heterozygous C3H mice leads to significant decreases in hippocampal GAD-65 and GABAA receptor levels, indicating that α7*nAChR expression level controls inhibitory circuit components in the hippocampus.\",\n      \"method\": \"Chrna7 heterozygous null mice; quantitative Western immunoblotting for GAD-65, GABAA receptors, GABA, GAT-1 in hippocampus\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean genetic KO/Het model with defined molecular phenotype, single lab, quantitative protein analysis\",\n      \"pmids\": [\"22314319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Reduced Chrna7 expression in C3H mice is associated with increases in hippocampal parvalbumin and GAD67, and complex alterations in GABAA receptor subunits (decreased α3, α4, and δ subunits in KO; increased δ in Het; increased γ2 in KO). These changes are sex- and gene-dose-dependent.\",\n      \"method\": \"Chrna7 wild-type, heterozygous, and knockout C3H mice; quantitative Western immunoblotting for parvalbumin, GAD67, and GABAA receptor subunits\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — graded genetic model (WT/Het/KO) with protein-level quantification, single lab\",\n      \"pmids\": [\"24836856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Gestational choline supplementation improves sensory inhibition via α7 nAChRs; DBA/2 mice heterozygous or null-mutant for Chrna7 fail to show improvement in sensory inhibition with choline supplementation, whereas wild-type mice do. This demonstrates that choline's effect on sensory inhibition requires functional CHRNA7.\",\n      \"method\": \"Chrna7 null mutation DBA/2 mice; gestational choline supplementation; auditory sensory inhibition testing; [125I]-α-bungarotoxin binding in hippocampus\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis using null mutation model, multiple genotypes, functional behavioral and receptor binding readouts; single lab\",\n      \"pmids\": [\"24462939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CHRNA7 mediates nicotine-induced signaling in ESCC cancer cells by activating the JAK2/STAT3 signaling pathway to enhance cancer stem cell properties. Dextromethorphan non-competitively inhibited nicotine binding to CHRNA7, while metformin downregulated CHRNA7 expression by antagonizing nicotine-induced promoter DNA hypomethylation.\",\n      \"method\": \"ESCC cell lines and mouse xenograft models; pharmacological inhibition with dextromethorphan and metformin; Western blot for JAK2/STAT3 pathway; promoter methylation analysis; cancer stem cell assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo models with mechanistic pathway analysis and epigenetic characterization; single lab\",\n      \"pmids\": [\"33603170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Arctic Aβ40 blocks the neuroprotective effect of nicotine mediated through CHRNA7 by inhibiting the ERK1/2 pathway downstream of CHRNA7. CHRNA7 knockdown by siRNA in SH-SY5Y cells abolished nicotine's neuroprotective effect, and ERK1/2 activation was shown to mediate neuroprotection against oxidative stress via CHRNA7.\",\n      \"method\": \"Human neuroblastoma SH-SY5Y cells; siRNA knockdown of CHRNA7; pharmacological nicotine stimulation; Western blot for ERK1/2 phosphorylation; cell viability/survival assays; oxidative stress challenge\",\n      \"journal\": \"Neurochemistry international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with defined pathway readout (ERK1/2), functional neuroprotection assay; single lab, single paper\",\n      \"pmids\": [\"28890319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"VNS-induced neuroprotection in permanent cerebral ischemia requires α7nAChR, which activates the JAK2/STAT3 anti-inflammatory pathway. Pharmacological antagonism of α7nAChR attenuated VNS neuroprotection and decreased p-JAK2 and p-STAT3 levels in ischemic penumbra; α7nAChR agonism partially substituted for VNS.\",\n      \"method\": \"Rat PMCAO model; α7nAChR antagonist and agonist pharmacology; Western blot for α7nAChR, p-JAK2, p-STAT3; neurological function scoring; cerebral infarct volume measurement\",\n      \"journal\": \"Medical science monitor\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological gain- and loss-of-function with defined downstream pathway readout in vivo; single lab\",\n      \"pmids\": [\"29274273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Chrna7 regulates nicotine conditioned place preference in mice. α7 knockout mice show nicotine CPP at sub-threshold doses, while gain-of-function α7 mice do not display nicotine preference. An α7-selective agonist (PHA-543613) dose-dependently blocked nicotine CPP, reversed by the selective antagonist MLA. Chrna7 KO in nucleus accumbens is associated with increased insulin signaling.\",\n      \"method\": \"Chrna7 KO and gain-of-function mouse models; nicotine conditioned place preference (CPP) behavioral assay; selective α7 agonist/antagonist pharmacology; microarray and qPCR of nucleus accumbens; Western blotting for insulin signaling\",\n      \"journal\": \"Genes, brain, and behavior\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological approaches with behavioral and molecular readouts; single lab\",\n      \"pmids\": [\"24289814\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CHRNA7 overexpression in LoVo colorectal cancer cells reduces cell migration and invasion via activation of the PI3K/Akt signaling pathway, accompanied by reduced MMP-1 and MMP-9 expression. Blocking PI3K/Akt with LY294002 restored migration/invasion in CHRNA7-overexpressing cells.\",\n      \"method\": \"CHRNA7 overexpression plasmid in LoVo cells; Transwell migration/invasion assays; Western blot and gelatin zymography for MMP-1, MMP-9; PI3K/Akt pathway pharmacological inhibition (LY294002)\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — overexpression with pharmacological pathway rescue, multiple functional assays; single lab\",\n      \"pmids\": [\"26719016\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Silencing of α7-nAChR (CHRNA7) in AGS gastric cancer cells by siRNA enhances ixabepilone-induced apoptosis, associated with failure to upregulate Bcl-2 and anti-apoptotic Mcl-1 isoform (which are upregulated in scrambled control cells after ixabepilone), and increased cleaved PARP. pAKT and AKT levels were similarly reduced in both groups by ixabepilone.\",\n      \"method\": \"siRNA knockdown of CHRNA7 in AGS cells; ixabepilone cytotoxicity (MTT assay); flow cytometry/annexin V apoptosis assay; Western blot for AKT, pAKT, Mcl-1, Bcl-2, Bad, Bax, cleaved PARP\",\n      \"journal\": \"Tumour biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single knockdown approach with Western blot, single lab, limited mechanistic depth\",\n      \"pmids\": [\"26790437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Chrna7 genotype is linked to α7 nicotinic receptor protein levels (measured by α-bungarotoxin binding) in hippocampus and striatum of F2 mice, but not to α7 RNA levels, suggesting the genetic influence on receptor expression operates at the post-transcriptional level.\",\n      \"method\": \"F2 mice from C3H/Ibg × DBA/2 cross; quantitative autoradiography of [125I]-α-bungarotoxin binding; quantitative in situ hybridization for α7 RNA; linkage analysis\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic linkage with parallel protein and RNA quantitation in F2 mapping population, multiple brain regions; single lab\",\n      \"pmids\": [\"19368846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"MeCP2-bound chromatin in the 15q11.2-13.3 region physically interacts (via 4C chromatin conformation capture) with two sites flanking CHRNA7 in neurons, and this interaction is lost upon neuronal differentiation. Reduced CHRNA7 expression was found in postmortem frontal cortex from Rett syndrome and autism patients, suggesting that long-range chromatin interactions with the PWS-IC modulate CHRNA7 transcription.\",\n      \"method\": \"Chromosome conformation capture on chip (4C) in human SH-SY5Y neuroblastoma cells; FISH to confirm PWS-IC/CHRNA7 interaction in neurons; qRT-PCR of CHRNA7 in postmortem human brain (Rett, autism, controls)\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — 4C chromatin interaction confirmed by FISH with functional gene expression correlate in human tissue; single lab\",\n      \"pmids\": [\"21840925\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DNA methylation at multiple regions of the CHRNA7 promoter regulates its transcription. Valproate (a mood stabilizer/HDAC inhibitor) causes demethylation of the CHRNA7 promoter and increases CHRNA7 expression in HeLa cells; combined valproate and nicotine treatment also increases expression in SH-SY5Y cells. Genotypic variants influence methylation levels at the CHRNA7 promoter.\",\n      \"method\": \"Bisulfite pyrosequencing of CHRNA7 promoter regions in human temporal cortex and cell lines; valproate treatment; qRT-PCR of CHRNA7 expression; correlation of methylation and expression\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological demethylation with parallel expression measurement, multiple regions and cell types; single lab\",\n      \"pmids\": [\"30974230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Farnesyl transferase inhibitor lonafarnib increases α7nAChR expression through inhibiting DNA methylation of CHRNA7 via the Ras-c-Jun-JNK pathway (reduced DNMT1), and independently increases α7nAChR membrane trafficking via CaMKII pathway, leading to enhanced ACh-evoked currents and spatial memory in mice.\",\n      \"method\": \"In vivo mouse lonafarnib administration; patch-clamp electrophysiology (ACh-evoked I_ACh) in hippocampal CA1; Western blot for DNMT1, p-JNK, p-c-Jun, α7nAChR expression and membrane fractionation; JNK activator and CaMKII inhibitor pharmacology; spatial memory testing\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — electrophysiology combined with mechanistic pathway analysis (JNK, DNMT1, CaMKII) and pharmacological rescue; single lab\",\n      \"pmids\": [\"33447242\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Chrna7 contains a putative neuronal transcriptional enhancer within the PWS/AS deletion region (intron 4 region). In a transgenic mouse model (TgPWS/TgAS) with deletion of this region, Chrna7 expression in brain is reduced ~1.7-fold, while expression in neonatal liver and spleen is paradoxically increased >15-fold due to transgene immunoglobulin enhancer effects. A Chrna7-Tg fusion transcript mapped the telomeric deletion breakpoint to Chrna7 intron 4.\",\n      \"method\": \"TgPWS/TgAS transgenic mouse model with large chromosomal deletion; RT-PCR and fusion transcript cloning; quantitative gene expression analysis across brain and peripheral tissues\",\n      \"journal\": \"BMC genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic model with mapped deletion breakpoint and quantitative expression analysis; single lab\",\n      \"pmids\": [\"16280085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In iPSC-derived cortical neurons from an autistic proband (but not his unaffected mother) carrying a 15q13.3 CHRNA7 duplication, CHRNA7 duplication causes enhanced neural progenitor proliferation, impaired neuronal differentiation/maturation/migration, and increased ER stress. Neuronal migration deficit could be pharmacologically rescued. Both affected and unaffected carriers showed increased action potential firing and elevated cholinergic activity consistent with increased homomeric CHRNA7 channel activity.\",\n      \"method\": \"iPSC-derived cortical excitatory and inhibitory neurons from proband, unaffected mother, and unrelated controls; electrophysiology; neuronal migration assay; ER stress markers; pharmacological rescue; single-cell RNA sequencing; gene expression analysis\",\n      \"journal\": \"BMC biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (electrophysiology, scRNAseq, migration, ER stress, pharmacological rescue) in human iPSC model; single lab but comprehensive\",\n      \"pmids\": [\"34320968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CHRNA7 and CHRFAM7A are expressed in SOX2+ radial glia progenitors in developing human cortex. nAChR activation increases radial glia (RG) proliferation while decreasing neuronal differentiation; nAChR knockdown has the opposite effect. YAP1 is identified as a downstream effector of nAChR signaling, and YAP1 inhibition reverses nicotine-induced phenotypic alterations in outer radial glia (oRG) cells. CHRNA7 and CHRFAM7A selectively modulate different transcriptional changes in excitatory neurons following nicotine exposure.\",\n      \"method\": \"Human cortical organotypic slice cultures and dissociated cultures; nAChR pharmacological activation and knockdown; single-cell RNA sequencing; YAP1 inhibitor pharmacological rescue; RG proliferation and differentiation assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — human cortical model with pharmacological and genetic manipulation plus scRNAseq; preprint, not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.04.10.647795\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SLURP1 (Secreted Ly-6/uPAR-Related Protein 1) is an endogenous ligand that acts on CHRNA7 in PDAC cells in a CHRNA7-dependent manner with anti-malignant effects, opposing the pro-malignant effects of nicotine. In CHRNA7-high cells, SLURP1 and nicotine abolish each other's effects through functional antagonism without reciprocally interfering with receptor binding or downstream signaling.\",\n      \"method\": \"CHRNA7-high COLO357 and PANC-1 cancer cell cultures; SLURP1 and nicotine treatment; receptor binding analysis; downstream signaling; cell viability/malignancy assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — cell culture-based functional antagonism without defined binding affinity or structural data; single lab\",\n      \"pmids\": [\"29545933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GTS-21 (a selective α7 nAChR agonist) promotes regulatory T cell (Treg) development from TCR-activated human CD4+ T cells. CHRNA7 mRNA was profoundly suppressed upon TCR activation (days 4-7 vs day 1), while CHRFAM7A (dominant-negative regulator) remained constant. GTS-21 did not alter CD4+ T cell proliferation but significantly promoted Treg development even with high dupα7 expression.\",\n      \"method\": \"Human CD4+ T cell culture; TCR activation; GTS-21 pharmacological treatment; flow cytometry for Treg markers; RT-PCR for CHRNA7 and CHRFAM7A mRNA\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pharmacological agonism in human T cells with functional Treg readout; no CHRNA7 KD control; single lab\",\n      \"pmids\": [\"37569633\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"α7nAChR activation in human granulosa cells (GCs) reduces hypoxia-induced elevations of IL-6, CXCL8, and IL-1B. CHRNA7 activation with selective agonist PNU 282987 acutely elevated intracellular Ca2+ in GCs, confirming functional receptor expression. Proteomic analysis revealed that CHRNA7 activation decreased several collagen protein levels in hypoxic GCs.\",\n      \"method\": \"Human granulosa cells from IVF patients; PNU 282987 pharmacological activation; Ca2+ imaging; cytokine mRNA measurement; proteomics; immunohistochemistry in human and primate ovaries\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional Ca2+ assay confirming receptor activity, pharmacological activation with cytokine and proteomic readouts; single lab\",\n      \"pmids\": [\"40847805\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CHRNA7 encodes the α7 subunit of the neuronal nicotinic acetylcholine receptor, a homo-pentameric ligand-gated ion channel that, upon activation by ACh, choline, or nicotine, mediates Ca2+ influx and activates downstream pathways including ERK1/2, JAK2/STAT3, PI3K/Akt, and YAP1 signaling; its transcription is regulated by AP-2α-mediated repression and DNA methylation of the proximal promoter; the human-specific partial duplicate CHRFAM7A co-assembles with α7 subunits to form non-conducting receptors that dominantly suppress channel function; receptor surface expression is subject to post-transcriptional regulation and ER-chaperone-dependent trafficking; and the receptor plays defined roles in hippocampal inhibitory circuit maintenance, sperm motility, immune/inflammatory modulation via the cholinergic anti-inflammatory pathway, neural progenitor proliferation versus neuronal differentiation (via YAP1), and nicotine reward behavior.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CHRNA7 encodes the α7 subunit of a neuronal nicotinic acetylcholine receptor that functions as a calcium-permeable ligand-gated channel whose activation triggers intracellular signaling cascades across neural, immune, reproductive, and oncogenic contexts [#1, #23]. Functional receptor output is tightly gated by gene dosage: both haploinsufficiency and overexpression reduce α7-associated calcium flux, the latter through ER chaperone induction, ER stress, and failure to incorporate accumulated α7 subunits into surface receptors [#1, #19]. The human-specific partial duplicate CHRFAM7A co-assembles with α7 to form ACh-silent, non-conducting receptors that dominantly suppress channel function while retaining α-bungarotoxin binding [#0]. CHRNA7 transcription is controlled by AP-2α-mediated repression of the proximal promoter and by inverse-correlated promoter DNA methylation, such that DNMT inhibition, methyl-donor depletion, or HDAC inhibitors de-repress expression [#2, #3, #16]; long-range MeCP2-dependent chromatin interactions with the 15q11.2-13.3 PWS imprinting region provide additional transcriptional control lost upon neuronal differentiation [#15]. Genetic determination of receptor level operates post-transcriptionally, affecting α-bungarotoxin-binding protein without changing RNA [#14]. Downstream, ligand-activated α7 engages ERK1/2 for neuroprotection against oxidative stress, JAK2/STAT3 in anti-inflammatory signaling and cancer stem-cell maintenance, PI3K/Akt in tumor cell migration and apoptosis resistance, and YAP1 to drive radial glia proliferation at the expense of neuronal differentiation [#9, #10, #8, #12, #20]. The receptor controls hippocampal inhibitory circuit composition (GAD, parvalbumin, GABAA subunits), sensory inhibition responsive to choline, sperm midpiece motility, nicotine reward behavior, and cholinergic anti-inflammatory cytokine suppression, and is acted upon by the endogenous ligand SLURP1 as a functional antagonist of nicotine [#5, #7, #4, #11, #23, #21].\"\n  ,\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Establishing whether α7 nAChR has a peripheral physiological role beyond the brain, the sperm motility phenotype showed the receptor functions as an ionotropic regulator in non-neural cells.\",\n      \"evidence\": \"Chrna7 null mouse with CASA motility analysis and fluorescent α-bungarotoxin localization to the sperm midpiece\",\n      \"pmids\": [\"15944242\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream signaling coupling Ca2+ to flagellar motility not defined\", \"No human sperm confirmation\", \"Whether CHRFAM7A modulates this peripheral function untested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Mapping how CHRNA7 transcription is embedded in the PWS/AS imprinting locus identified an intronic neuronal enhancer, framing the gene's tissue-specific regulation within a complex genomic region.\",\n      \"evidence\": \"TgPWS/TgAS transgenic mouse with mapped intron 4 breakpoint and quantitative tissue expression\",\n      \"pmids\": [\"16280085\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Enhancer not validated in isolation\", \"Trans-acting factors binding the enhancer unknown\", \"Human relevance of the murine breakpoint unclear\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Resolving the level at which genetic variation sets receptor abundance, linkage analysis showed Chrna7 genotype controls α-bungarotoxin-binding protein but not RNA, pinpointing post-transcriptional regulation.\",\n      \"evidence\": \"F2 mouse mapping cross with parallel autoradiographic protein and in situ RNA quantitation\",\n      \"pmids\": [\"19368846\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific post-transcriptional mechanism (translation, assembly, trafficking) not identified\", \"Causal variant not cloned\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defining the function of the human-specific duplicate, co-expression demonstrated CHRFAM7A forms ACh-silent receptors that dominantly suppress α7 channel function, explaining a uniquely human modulator of cholinergic signaling.\",\n      \"evidence\": \"Electrophysiology in cell lines and Xenopus oocytes, α-bungarotoxin binding, and PNU-120596 allosteric pharmacology\",\n      \"pmids\": [\"21718690\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Subunit stoichiometry of mixed receptors not resolved\", \"In vivo contribution in human tissue not quantified\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identifying transcriptional and epigenetic control, AP-2α was shown to repress the proximal promoter and promoter DNA methylation was shown to inversely set expression, establishing two layers of CHRNA7 regulation.\",\n      \"evidence\": \"Promoter mutagenesis, ChIP/EMSA/supershift with AP-2α KD/OE; bisulfite sequencing, DNMT inhibitors, and methyl-donor manipulation\",\n      \"pmids\": [\"21979958\", \"22052086\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals that recruit AP-2α or set methylation in vivo unknown\", \"Interplay between the two mechanisms not dissected\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Connecting CHRNA7 to neurodevelopmental disease regulation, MeCP2-dependent long-range chromatin contacts with the PWS imprinting center were shown to modulate transcription and to correlate with reduced expression in Rett and autism brain.\",\n      \"evidence\": \"4C chromatin conformation capture confirmed by FISH in neurons plus qRT-PCR in postmortem human cortex\",\n      \"pmids\": [\"21840925\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal direction between chromatin loop loss and expression not proven\", \"Mechanism linking the loop to disease phenotype unestablished\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Testing what circuit-level role α7 plays, dosage reduction was shown to lower hippocampal inhibitory components, indicating the receptor maintains inhibitory circuit composition.\",\n      \"evidence\": \"Quantitative immunoblotting of GAD-65 and GABAA receptors in Chrna7 heterozygous hippocampus\",\n      \"pmids\": [\"22314319\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional electrophysiological consequence not measured here\", \"Cell-type origin of changes unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Determining α7's role in addiction, bidirectional genetic and pharmacological manipulation showed Chrna7 constrains nicotine reward behavior.\",\n      \"evidence\": \"Chrna7 KO and gain-of-function mice in nicotine CPP with selective agonist/antagonist and nucleus accumbens expression profiling\",\n      \"pmids\": [\"24289814\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Circuit through which α7 limits reward not defined\", \"Significance of accumbens insulin signaling change unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Extending the inhibitory-circuit and behavioral roles, graded genetic models showed dose- and sex-dependent GABAergic remodeling and demonstrated that choline-mediated improvement of sensory inhibition requires functional α7.\",\n      \"evidence\": \"WT/Het/KO immunoblotting for GABAA subunits, parvalbumin, GAD67; gestational choline supplementation with auditory sensory inhibition and hippocampal α-bungarotoxin binding\",\n      \"pmids\": [\"24836856\", \"24462939\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking receptor level to subunit changes unknown\", \"Developmental window of choline action not delimited\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Mapping downstream effectors, distinct studies established that ligand-activated α7 signals through ERK1/2 for neuroprotection and through JAK2/STAT3 for anti-inflammatory neuroprotection and cancer stem-cell maintenance.\",\n      \"evidence\": \"siRNA knockdown in SH-SY5Y with ERK1/2 readout; rat PMCAO with VNS and α7 agonist/antagonist measuring p-JAK2/p-STAT3; ESCC cells/xenografts with JAK2/STAT3 and promoter methylation analysis\",\n      \"pmids\": [\"28890319\", \"29274273\", \"33603170\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical link from channel to each kinase cascade not shown\", \"Cell-type specificity of pathway selection unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Clarifying why gene dosage gain is deleterious, iPSC neural progenitors with 15q13.3 duplication revealed that overexpression induces ER chaperones and ER stress, trapping α7 subunits and reducing calcium flux just as haploinsufficiency does.\",\n      \"evidence\": \"iPSC-derived NPCs from deletion and duplication carriers with calcium flux, chaperone transcriptomics, and ER stress markers\",\n      \"pmids\": [\"29129316\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of chaperones limiting assembly not pinned down\", \"Whether CHRFAM7A contributes to the duplication phenotype not isolated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identifying an endogenous physiological ligand, SLURP1 was shown to act through CHRNA7 as a functional antagonist of nicotine with opposing anti-malignant effects.\",\n      \"evidence\": \"SLURP1 and nicotine treatment of CHRNA7-high PDAC cells with binding and downstream signaling analysis\",\n      \"pmids\": [\"29545933\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No defined binding affinity or structural interaction\", \"CHRNA7-dependence shown without knockdown rescue across all readouts\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Refining epigenetic control, promoter methylation across multiple regions was shown to be pharmacologically reversible by valproate with corresponding expression gains, reinforcing methylation as a tunable regulatory switch.\",\n      \"evidence\": \"Bisulfite pyrosequencing of human cortex and cell lines with valproate treatment and qRT-PCR\",\n      \"pmids\": [\"30974230\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus HDAC-mediated effect of valproate not separated\", \"Genotype-methylation causality not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrating that expression and trafficking can be simultaneously enhanced therapeutically, lonafarnib was shown to de-repress CHRNA7 via Ras-c-Jun-JNK/DNMT1 and to boost membrane trafficking via CaMKII, increasing ACh-evoked currents and memory.\",\n      \"evidence\": \"In vivo mouse lonafarnib with CA1 patch-clamp, DNMT1/JNK/c-Jun immunoblotting, membrane fractionation, and pathway pharmacology\",\n      \"pmids\": [\"33447242\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether transcriptional and trafficking effects are mechanistically independent in vivo not fully separated\", \"Off-target farnesylation effects not excluded\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Establishing the developmental consequence of duplication in patient cells, iPSC cortical neurons showed CHRNA7 duplication enhances progenitor proliferation while impairing differentiation, maturation, and migration alongside ER stress.\",\n      \"evidence\": \"iPSC-derived neurons from proband, unaffected mother, and controls with electrophysiology, migration assay, scRNAseq, ER stress markers, and pharmacological rescue\",\n      \"pmids\": [\"34320968\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why proband and unaffected mother diverge phenotypically not resolved\", \"Effector linking channel activity to migration deficit not identified here\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identifying the proliferation-versus-differentiation effector, nAChR signaling in human radial glia was shown to act through YAP1 to favor proliferation, with CHRNA7 and CHRFAM7A driving distinct transcriptional responses to nicotine.\",\n      \"evidence\": \"Human cortical organotypic and dissociated cultures with nAChR activation/knockdown, scRNAseq, and YAP1 inhibitor rescue (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.04.10.647795\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, not yet peer-reviewed\", \"Biochemical link from channel Ca2+ to YAP1 activation not defined\", \"Divergence of CHRNA7 versus CHRFAM7A transcriptional programs not mechanistically explained\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the diverse downstream cascades (ERK1/2, JAK2/STAT3, PI3K/Akt, YAP1) are selected by α7 channel activity in different cell types, and how CHRFAM7A and ER-chaperone trafficking quantitatively tune surface receptor output in human tissue, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model linking channel gating to pathway choice\", \"Quantitative contribution of CHRFAM7A to native human receptor pools unmeasured\", \"Identity of the ER chaperones limiting assembly not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005230\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 23]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 4, 17]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [1, 19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [5, 6, 7, 17]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 9, 10, 12]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [10, 22, 23]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 3, 15, 16]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [19, 20]}\n    ],\n    \"complexes\": [\"α7 homopentameric nicotinic acetylcholine receptor\", \"α7/CHRFAM7A heteromeric (non-conducting) receptor\"],\n    \"partners\": [\"CHRFAM7A\", \"SLURP1\", \"AP-2α\", \"MeCP2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}